It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
While the application of early screening and HPV vaccines has reduced the incidence and mortality rates of cervical cancer, it remains the third most common carcinoma and fourth leading cause of cancer-associated death among women worldwide. The precise mechanisms underlying progression of cervical cancer are not fully understood at present. Here, we detected significant down-regulation of 15-hydroxyprostaglandin dehydrogenase (HPGD) in cervical cancer tissues. Overexpression of HPGD inhibited cervical cancer cell proliferation, migration and anchorage-independent growth to a significant extent. To clarify the mechanisms underlying HPGD down-regulation in cervical cancer, miRNA microarray, bioinformatics and luciferase reporter analyses were performed. HPGD was identified as a direct target of miR-146b-3p displaying up-regulation in cervical cancer tissues. Similar to the effects of HPGD overexpression, down-regulation of miR-146b-3p strongly suppressed proliferation, migration and anchorage-independent growth of cervical cancer cells. Furthermore, HPGD negatively regulated activities of STAT3 and AKT that promote cervical cancer cell proliferation. Notably, HPV oncogenes E6 and E7 were determined as potential contributory factors to these alterations. Our results collectively suggest that the HPGD/miR-146b-3p axis plays a significant role in cervical cancer and may serve as a potentially effective therapeutic target.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 Nanjing Medical University, State Key Laboratory of Reproductive Medicine, Nanjing, P. R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); Quzhou College of Technology, Medical School, Quzhou, P. R. China (GRID:grid.469581.7) (ISNI:0000 0004 1776 2538)
2 Nanjing Medical University, Key Laboratory of Pathogen Biology of Jiangsu Province, Nanjing, P. R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); Nanjing Medical University, Department of Microbiology, Nanjing, P. R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
3 Quzhou College of Technology, Medical School, Quzhou, P. R. China (GRID:grid.469581.7) (ISNI:0000 0004 1776 2538)
4 Nanjing Medical University, State Key Laboratory of Reproductive Medicine, Nanjing, P. R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); Nanjing Medical University, Key Laboratory of Pathogen Biology of Jiangsu Province, Nanjing, P. R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984); Nanjing Medical University, Department of Microbiology, Nanjing, P. R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)
5 Geriatric Hospital of Nanjing Medical University, Department of Hematology and Oncology, Department of Geriatric Lung Cancer Research Laboratory, Nanjing, P. R. China (GRID:grid.89957.3a) (ISNI:0000 0000 9255 8984)